Market Cap 75.00M
Revenue (ttm) 0.00
Net Income (ttm) -24.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.34
Volume 58,000
Avg Vol 135,992
Day's Range N/A - N/A
Shares Out 92.98M
Stochastic %K 34%
Beta 3.56
Analysts Strong Sell
Price Target $4.00

Company Profile

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 908 967 6677
Address:
11 Commerce Drive, First Floor, Cranford, United States
Noname2022
Noname2022 May. 30 at 6:15 PM
$CRMD $CTOR $CTXR Interesting breadcrumb: a Citius post about funding LYMPHIR commercialization drew engagement from multiple CorMedix/Melinta commercial personnel across Operations, Value & Access, Marketing, KAM, and Compliance. Could be nothing, but it’s more overlap than I’d expect for a niche oncology launch.
1 · Reply
TwongStocks
TwongStocks May. 29 at 9:04 PM
$CTOR The Definitive Notice of Stockholder Action by Written Consent was filed this afternoon. Approval of the warrants is effective June 18. https://www.sec.gov/Archives/edgar/data/1851484/000121390026062911/ea0292248-def14c_citius.htm Summary 👇👇
0 · Reply
Merlintrader
Merlintrader May. 27 at 12:07 PM
$LPCN Three Biotech Data Presentations to Watch: Precision BioSciences, Lipocine and Citius Oncology $DTIL $LPCN $CTOR https://www.merlintrader.com/biotech-data-presentations-may2026/
1 · Reply
Bronco6970
Bronco6970 May. 26 at 6:40 PM
$CTOR $CTXR I’m convinced Twong is Leonard, Leonard is Twong. Finkle is Einhorn, Einhorn is Finkle 🤢
1 · Reply
TwongStocks
TwongStocks May. 26 at 12:02 PM
$CTOR $CTXR Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting https://citiusonc.com/news/news-details/2026/Citius-Oncology-Announces-Presentation-of-LYMPHIR-Phase-1-Combination-Study-Data-at-the-2026-American-Society-of-Clinical-Oncology-Annual-Meeting/default.aspx Abstract was release last Thursday 👇
0 · Reply
TwongStocks
TwongStocks May. 21 at 9:49 PM
$CTOR Lymphir Phase 1 data, abstract from ASCO https://www.asco.org/abstracts-presentations/257907 Depletion of T-regulatory cells by denileukin diftitox-cxdl (E7777) in combination with pembrolizumab in relapsed/refractory (r/r) gynecologic malignancies: Phase 1 study results.
0 · Reply
TwongStocks
TwongStocks May. 19 at 9:07 PM
$CTOR Citius Oncology files Preliminary Notice of Stockholder Action By Written Consent to approve exercise of warrants issued May 5 https://www.sec.gov/Archives/edgar/data/1851484/000121390026059053/ea0290807-pre14c_citius.htm On May 5, Citius Oncology entered into a loan agreement and warrant transaction. Per their SEC filing filed on May 6, CTOR is required to seek shareholder approval of the warrants issued. Today, they filed a Preliminary Notice of Stockholder Action by Written Consent. The shareholder approval of the warrants will pass because the majority shareholder (parent company $CTXR ) will vote in favor. Therefore, no action or vote will be required of CTOR shareholders. Dates in the preliminary filing are still redacted. They will be finalized when CTOR files the definitive notice with the SEC.
2 · Reply
np_stocks
np_stocks May. 19 at 1:56 PM
$CTOR $CTXR to the world watching and seeing this do not spend your hard earned money on this stock. 🚨 🔔 ‼️
0 · Reply
SweStonk
SweStonk May. 19 at 9:53 AM
$CTOR The dump havent even started and dilution on the horizon. R/S is imminent at this point for both $CTXR and CTOR. Never trade with hope. Some companies fail. U all have way better companies to invest in with same reward but without the risk of them going bankrupt. I have warned you all the way from $70 @ share...
1 · Reply
ekpemofolo
ekpemofolo May. 18 at 5:55 PM
$CTOR I will continue my mildly bullish rant. Asking for an analysis of the numbers in light of the initial December sales, AI spits out the following: The Quarter-over-Quarter Decline: The sequential drop from $3.94 million to $1.67 million reflects the typical pharmaceutical launch curve. Specialty distributors placed major, large-scale initial orders in December 2025 to stock their channels. Inventory Digestion: During the three months ended March 31, 2026, those distributors were working through that initial December inventory while transition to patient-driven "repeat orders" began taking shape. Distorted Expectations: This front-loaded revenue in December made the subsequent three-month performance look artificially low to the market, leading to the headline-grabbing revenue miss against initial analyst expectations.
0 · Reply
Latest News on CTOR
Citius Oncology provides commercial update on lymphir launch

2026-03-31T13:40:30.000Z - 2 months ago

Citius Oncology provides commercial update on lymphir launch


Citius Oncology reports Q1 EPS (6c) vs. (9c) last year

2026-02-13T13:16:23.000Z - 3 months ago

Citius Oncology reports Q1 EPS (6c) vs. (9c) last year

CTXR


Citius Oncology reports FY25 EPS (34c) vs. (31c) last year

2025-12-23T21:40:21.000Z - 5 months ago

Citius Oncology reports FY25 EPS (34c) vs. (31c) last year


Citius Oncology announces U.S. commercial launch of LYMPHIR

2025-12-01T17:10:12.000Z - 6 months ago

Citius Oncology announces U.S. commercial launch of LYMPHIR


Citius Oncology  upgraded to Buy from Hold at Maxim

2025-09-23T11:30:17.000Z - 8 months ago

Citius Oncology upgraded to Buy from Hold at Maxim


Noname2022
Noname2022 May. 30 at 6:15 PM
$CRMD $CTOR $CTXR Interesting breadcrumb: a Citius post about funding LYMPHIR commercialization drew engagement from multiple CorMedix/Melinta commercial personnel across Operations, Value & Access, Marketing, KAM, and Compliance. Could be nothing, but it’s more overlap than I’d expect for a niche oncology launch.
1 · Reply
TwongStocks
TwongStocks May. 29 at 9:04 PM
$CTOR The Definitive Notice of Stockholder Action by Written Consent was filed this afternoon. Approval of the warrants is effective June 18. https://www.sec.gov/Archives/edgar/data/1851484/000121390026062911/ea0292248-def14c_citius.htm Summary 👇👇
0 · Reply
Merlintrader
Merlintrader May. 27 at 12:07 PM
$LPCN Three Biotech Data Presentations to Watch: Precision BioSciences, Lipocine and Citius Oncology $DTIL $LPCN $CTOR https://www.merlintrader.com/biotech-data-presentations-may2026/
1 · Reply
Bronco6970
Bronco6970 May. 26 at 6:40 PM
$CTOR $CTXR I’m convinced Twong is Leonard, Leonard is Twong. Finkle is Einhorn, Einhorn is Finkle 🤢
1 · Reply
TwongStocks
TwongStocks May. 26 at 12:02 PM
$CTOR $CTXR Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting https://citiusonc.com/news/news-details/2026/Citius-Oncology-Announces-Presentation-of-LYMPHIR-Phase-1-Combination-Study-Data-at-the-2026-American-Society-of-Clinical-Oncology-Annual-Meeting/default.aspx Abstract was release last Thursday 👇
0 · Reply
TwongStocks
TwongStocks May. 21 at 9:49 PM
$CTOR Lymphir Phase 1 data, abstract from ASCO https://www.asco.org/abstracts-presentations/257907 Depletion of T-regulatory cells by denileukin diftitox-cxdl (E7777) in combination with pembrolizumab in relapsed/refractory (r/r) gynecologic malignancies: Phase 1 study results.
0 · Reply
TwongStocks
TwongStocks May. 19 at 9:07 PM
$CTOR Citius Oncology files Preliminary Notice of Stockholder Action By Written Consent to approve exercise of warrants issued May 5 https://www.sec.gov/Archives/edgar/data/1851484/000121390026059053/ea0290807-pre14c_citius.htm On May 5, Citius Oncology entered into a loan agreement and warrant transaction. Per their SEC filing filed on May 6, CTOR is required to seek shareholder approval of the warrants issued. Today, they filed a Preliminary Notice of Stockholder Action by Written Consent. The shareholder approval of the warrants will pass because the majority shareholder (parent company $CTXR ) will vote in favor. Therefore, no action or vote will be required of CTOR shareholders. Dates in the preliminary filing are still redacted. They will be finalized when CTOR files the definitive notice with the SEC.
2 · Reply
np_stocks
np_stocks May. 19 at 1:56 PM
$CTOR $CTXR to the world watching and seeing this do not spend your hard earned money on this stock. 🚨 🔔 ‼️
0 · Reply
SweStonk
SweStonk May. 19 at 9:53 AM
$CTOR The dump havent even started and dilution on the horizon. R/S is imminent at this point for both $CTXR and CTOR. Never trade with hope. Some companies fail. U all have way better companies to invest in with same reward but without the risk of them going bankrupt. I have warned you all the way from $70 @ share...
1 · Reply
ekpemofolo
ekpemofolo May. 18 at 5:55 PM
$CTOR I will continue my mildly bullish rant. Asking for an analysis of the numbers in light of the initial December sales, AI spits out the following: The Quarter-over-Quarter Decline: The sequential drop from $3.94 million to $1.67 million reflects the typical pharmaceutical launch curve. Specialty distributors placed major, large-scale initial orders in December 2025 to stock their channels. Inventory Digestion: During the three months ended March 31, 2026, those distributors were working through that initial December inventory while transition to patient-driven "repeat orders" began taking shape. Distorted Expectations: This front-loaded revenue in December made the subsequent three-month performance look artificially low to the market, leading to the headline-grabbing revenue miss against initial analyst expectations.
0 · Reply
ekpemofolo
ekpemofolo May. 18 at 4:18 PM
$CTOR The correct calculation is 4 months of sales = 5.6 m. Assuming no growth at all, it translates to about 17m per year. The market average for similar companies: market cap is x8 - x10 the annual revenue. Which is 136-170 m or more than $1.5 per share.
1 · Reply
SweStonk
SweStonk May. 18 at 3:36 PM
$CTOR Three months 1.6m in sales. ToWould you sell a slamdunk approval with sales expected the first year to yeald $100M for $40M⁸89
0 · Reply
TwongStocks
TwongStocks May. 15 at 9:59 PM
$CTOR $CTXR I completely missed this in the 10-Q. Their CMO terminated the contract due to breach of payment. I noticed that the operating expenses went up dramatically last qtr. From $8.4M Oct-Dec to $29.95M Jan-Mar. The reason is they had to pay a termination fee to their contract manufacturer. The manufacturing agreement was terminated in Feb due to a breach of payment by Citius. As a result of the breach, CTOR had to pay termination fees of $20.1M. These charges were included in last qtr's G&A expenses, which is why operating expenses were so high. In March, the CMO gave notice that it terminated all production and decommissioned the manufacturing lines. CTOR is evaluating new BDS suppliers and anticipates signing a LOI with a new CMO by June 30. "At this time, based on stock on hand and availability of alternate suppliers, we anticipate no interruption in commercial supply for the foreseeable future."
4 · Reply
NYC100
NYC100 May. 15 at 9:17 PM
$CTOR $CTXR article said from January to March 
1 · Reply
SKEETER_1
SKEETER_1 May. 15 at 8:53 PM
$CTOR delisting soon. Request for extension then reverse split, absolute trash earnings. Specifically released end of day Friday so you cant sell shares. Even if sales increased 100% you through the year thays still not enough to cover management salary. And now we re in debt 36 mil this is a disaster.
0 · Reply
TwongStocks
TwongStocks May. 15 at 8:51 PM
10-Q filings for both companies $CTXR https://www.sec.gov/ix?doc=/Archives/edgar/data/1506251/000121390026057842/ea0290552-10q_citius.htm $CTOR https://www.sec.gov/ix?doc=/Archives/edgar/data/1851484/000121390026057841/ea0290553-10q_citius.htm Some items in the 10-Qs that were not mentioned in the PRs: • 10-Qs for both companies confirm that the quarterly revenue was only $1.67M (see screenshots). They tried to make it sound better in the PRs by including the Dec numbers 😂 • As of May 14, CTXR has 27,452,570 shares outstanding • As of May 14, CTOR has 92,981,204 shares outstanding • EISAI money owed: "On December 15, 2025, we paid Eisai the balance of the outstanding milestone approval fee and accumulated interest on the license fee. On March 30, 2026 we paid Eisai $500,000 against the accounts payable balance. At March 31, 2026, we owe Eisai for other unpaid invoices, consisting of $2,200,000 of accounts payable and $4,062,481 of accrued expenses." • REDDY money owed: "At March 31, 2026, we owe Dr. Reddy’s $17,650,000 representing the balance of the approval milestone."
0 · Reply
TwongStocks
TwongStocks May. 15 at 8:32 PM
Citius earnings releases for FY2026 Q2 (Jan-Mar). $CTXR: https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-reports-fiscal-second-quarter-2026-financial-results-and-provides-business-update-302773890.html $CTOR: https://www.prnewswire.com/news-releases/citius-oncology-inc-reports-fiscal-second-quarter-2026-financial-results-and-provides-business-update-302773892.html • Lymphir sales for Dec-Mar was $5.6M. They already reported revenue of $3.9M in Dec, so it was $1.7M from Jan-Mar. • Both companies report a cash runway through November 2026
0 · Reply
SuperGreenToday
SuperGreenToday May. 15 at 3:25 AM
1 · Reply
NYC100
NYC100 May. 14 at 6:29 PM
0 · Reply
ekpemofolo
ekpemofolo May. 14 at 5:36 PM
$CTOR chatgpt answer to the question "if they meet the revenue predictions, what will be the stock price according to data from similar companies?" gives a positive outlook. Let's see how it plays out.
0 · Reply
TwongStocks
TwongStocks May. 14 at 1:14 PM
$CTOR Looks like they are also starting to build up their MSL team https://www.linkedin.com/posts/christy-smith-dnp-acnp-bc-8354a321_hiring-msl-oncology-share-7460481650670501890-PJ4D?utm_source=screenshot_social_share
0 · Reply
donein12
donein12 May. 13 at 6:58 PM
$CTOR Strong possibility CTOR will release their QTR. financials after MKT. close today or Pre market tomorrow. A chance they could be released before the close today.
0 · Reply